Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: A post hoc analysis of clinical trials in type 2 diabetes mellitus

Endocrine Practice

Volumn 16, Issue 5, 2010, Pages 818-828

  Davidson, Jaime A ^a   Lacaya, Lyndon B ^b   Jiang, Honghua ^b   Heilmann, Cory R ^b   Scism Bacon, Jamie L ^b   Gates, Jeffrey R ^c   Jackson, Jeffrey A ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Lilly USA   (United States)

^c Bioscience Research Section   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; CAUCASIAN; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HISPANIC; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; WEIGHT CHANGE;

ADULT; AGED; AGED, 80 AND OVER; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; ETHNIC GROUPS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78149356297     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09285.OR     Document Type: Article

References (36)

1. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U. S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009;32:287-294.
2. Oldroyd J, Banerjee M, Heald A, Cruickshank K. Diabetes and ethnic minorities. Postgrad Med J. 2005;81:486-490.
3. Dreyer G, Hull S, Aitken Z, Chesser A, Yaqoob MM. The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease. QJM. 2009;102:261-269.
4. Raymond NT, Varadhan L, Reynold DR, et al; UK Asian Diabetes Study Retinopathy Study Group. Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: a cross-sectional study. Diabetes Care. 2009;32:410-415.
5. Lanting LC, Joung IM, Mackenbach JP, Lamberts SW, Bootsma AH. Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: A review. Diabetes Care. 2005;28:2280-2288.
6. Emanuele N, Sacks J, Klein R, et al; Veterans Affairs Diabetes Trial Group. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care. 2005;28:1954-1958.
7. Herman WH, Dungan KM, Wolffenbuttel BH, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1, 5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:1689-1694.
8. Kirk JK, Passmore LV, Bell RA, et al. Disparities in A1C levels between Hispanic and non-Hispanic white adults with diabetes: A meta-analysis. Diabetes Care. 2008;31:240-246.
9. Kirk JK, Bell RA, Bertoni AG, et al. A qualitative review of studies of diabetes preventive care among minority patients in the United States, 1993-2003. Am J Manag Care. 2005;11:349-360.
10. Manna DR, Bruijnzeels MA, Mokkink HG, Berg M. Ethnic specifc recommendations in clinical practice guidelines: A frst exploratory comparison between guidelines from the USA, Canada, the UK, and the Netherlands. Qual Saf Health Care. 2003;12:353-358.
11. Chen ML. Ethnic or racial differences revisited: Impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2006;45:957-964.
12. McBean AM, Li S, Gilbertson DT, Collins AJ. Differences in diabetes prevalence, incidence, and mortality among the elderly of four racial/ethnic groups: Whites, blacks, hispanics, and asians. Diabetes Care. 2004;27:2317-2324.
13. Colvin-Adams M, Taylor AL. Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure. Cleve Clin J Med. 2007;74:227-234.
14. Roach P, Trautmann M, Anderson J; The LM Study Group. Lower incidence of nocturnal hypoglycemia during treatment with a novel protamine-based formulation of insulin lispro. Diabetes. 1998;47(Suppl 1): A92. [Abstract]
15. ® Mix25 Spanish Study Group. Improved glycaemic control without increased risk of hypoglycaemia with a 25% insulin/lispro 75% NPL mixture twice daily compared with NPH twice daily in patients with type 2 diabetes. J Appl Ther Res. 2004:4:3-9. [Abstract]
16. ™ improves glycemic control in patients with type 2 diabetes and inadequacy of oral agent combination therapy. Diabetes Res Clin Pract. 2000;50(Suppl 1): S43. [Abstract]
17. Herz M, Sun B, Milicevic Z, et al. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. Clin Ther. 2002;24:73-86.
18. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;25:2034-2044.
19. ® Mix 25 versus basal human insulin: A doubleblind study. J Appl Ther Res. 2004;4:19-26.
20. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med. 2005;22:374-381.
21. Malone JK, Beattie SD, Campaigne BN, Johnson PA, Howard AS, Milicevic Z. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract. 2003;62:187-195.
22. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre-and postprandial blood glucose levels in patients with type 2 diabetes: A multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther. 2007;29:2349-2364.
23. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31:20-25.
24. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925-926.
25. Davis TM, Cull CA, Holman RR; U. K. Prospective Diabetes Study (UKPDS) Group. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the frst 9 years of type 2 diabetes: U. K. Prospective Diabetes Study (UKPDS 55). Diabetes Care. 2001;24:1167-1174.
26. Karalliedde J, Smith A, Viberti G. Determinants of response to insulin therapy following failure of oral agents in type 2 diabetes. Diabetes Care. 2005;28:2589-2590.
27. Agrawal L, Emanuele NV, Abraira C, et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care. 1998;21:510-515.
28. Rhee MK, Ziemer DC, Caudle J, Kolm P, Phillips LS. Use of a uniform treatment algorithm abolishes racial disparities in glycemic control. Diabetes Educ. 2008;34:655-663.
29. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE; American Diabetes Association GENNID Study Group. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U. S. Diabetes. 2002;51:2170-2178.
30. Chiu KC, Cohan P, Lee NP, Chuang LM. Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. Diabetes Care. 2000;23:1353-1358.
31. Razak F, Anand SS, Shannon H, et al. Defining obesity cut points in a multiethnic population. Circulation. 2007;115:2111-2118.
32. Raji A, Gerhard-Herman MD, Warren M, et al. Insulin resistance and vascular dysfunction in nondiabetic Asian Indians. J Clin Endocrinol Metab. 2004;89:3965-3972.
33. Fall CH. Non-industrialised countries and affluence. Br Med Bull. 2001;60:33-50.
34. Lebovitz HE, Austin MM, Blonde L, et al; ACE/AACE Diabetes Recommendations Implementation Writing Committee. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: Consensus conference recommendations. Endocr Pract. 2006;12(Suppl 1):6-12.
35. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
36. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.